First-in-class drugs with addressable worldwide market of tens of millions of patients per year who suffer heart attack or stroke.
Ability of a single drug class to address multiple diseases enables staged clinical development with continuous value creation.
Other potential indications: traumatic head injury, hypoxic brain injury (cerebral palsy), retinal artery thrombosis, kidney artery thrombosis, cardiac and brain surgery, endarterectomy and heart valve replacement.
Key asset protected by patents granted globally.
Company Details
- Employees
- 15
- Founded
- -
- Address
- Brisbane, Qld, Au
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Keywords
- Pharmaceutical, molecules, peptide, hi1a, research, heart attack, stroke, ischemic, start up, blood, brain, venom, spider.
- HQ
- Brisbane, QLD
Infensa Bioscience Questions
Infensa Bioscience's website is https://www.infensabioscience.com
Infensa Bioscience's LinkedIn profile is https://au.linkedin.com/company/infensa-bioscience
Infensa Bioscience has
15 employees.
View email and phone details for 15
employees at Infensa Bioscience.
Infensa Bioscience's industry is
Biotechnology Research
Infensa Bioscience's top competitors are
Qimr Berghofer,
Advancell,
Life Sciences Queensland Ltd (Lsq),
Protagonist Therapeutics,
Uq Institute For Molecular Bioscience,
Microba Life Sciences,
Vicebio,
Vaxxas,
Translational Research Institute Australia,
Microbio.
Infensa Bioscience's categories are Biotechnology Research
Infensa Bioscience's founding year is 2021
